Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This entry refers to a predicted non-coding RNA transcript annotated on the antisense strand of the SIPA1L3 locus. There is no experimental evidence that this transcript encodes a functional protein or plays a recognized biological role. It is not considered a druggable target or known to participate in canonical molecular pathways. Most available information refers to its annotation status in genome databases, rather than any validated physiological or pathological function. ENSG00000268764 is a transcript annotated by Ensembl as "novel transcript, antisense to SIPA1L3", but there is no evidence that it encodes a protein or has any known biological or disease relevance. SIPA1L3 (ENSG00000105738), the sense gene, encodes a Rap GTPase-activating protein involved in lens morphogenesis and cellular adhesion, but the antisense transcript does not share these established functions[1][4][7]. The record is incomplete for drug discovery, lacking properties of a validated target, known biological function, or disease association, and therefore is not a therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on novel transcript, antisense to SIPA1L3.